iCFO Capital Global recently partnered with First Person Solutions to raise $1M.

SAN DIEGO, CALIFORNIA - iCFO Capital Global, Inc., recently partnered with First Person Solutions to raise $1M  from iCFO Capital Global investor network nationwide.

FirstPersonSolutions has developed a Botanical anti-inflammatory shown to treat chronic Lyme disease far faster, cheaper, and more successfully than any other treatments.  This is manufactured by our subsidiary in India. In conjunction with several leading Lyme doctors, we have enrolled fifty Lyme patients into a research study. We are seeking investment to launch into the North American chronic Lyme market.

Key Company Highlights:

• There are currently no known allopathic treatments or cures for chronic Lyme disease.  Natural treatments take months to produce results and are not always effective,  CelWel delivers excellent results, in many cases within forty-eight hours.
• Courses of natural treatments for Lyme cost thousands of dollars.  Treating chronic Lyme with CelWel costs less than one hundred dollars.
• The management team has many years of experience marketing consumer products.  Joel Adams has experience boot-strapping startups.
• CelWel is the first advancement in anti-inflammatories in over fifty years and has many uses beyond chronic Lyme.  CelWel can save lives and is potentially the answer to an outbreak of a new, currently unknown, disease.
• CelWel is the first treatment that combines allopathic, homeopathic, and natural medicines.  This is the first truly integrative health product.
• CelWel has a very low cost of production, under $0.60 per box, allowing for high gross margins.
• FirstPersonSolutions will be a very attractive buyout opportunity for many large consumer products companies